Selecting the Right Tool for the Right Job: Which Response Criteria Better Predicts Survival of Patients Treated with Transarterial Radioembolization?

摘要

Improving survival is the main goal of all anticancer therapy, but estimating overall survival is not easy because it necessitates a relatively long follow-up period. Furthermore, the impact of a certain therapy on overall survival is diluted by subsequent treatments for progression. Thus, evaluation of tumor response is a surrogate indicator to identify which patients are most likely to benefit from, and survive longer after receiving, anticancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is considered the standard for response evaluation in most solid cancers.